Biosimilars – Forecast – Ophthalmology
In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Ophthalmology
- Market forecast in the major pharmaceutical markets
- Major-market forecast: ophthalmology biologics
- Terminology
- Overarching forecast assumptions
- Overview of ophthalmology biological brands in forecast
- Overview of approved ophthalmology biologics
- Biosimilar entry assumptions for ophthalmology biologics
- Overview of biosimilars in ophthalmology disease assumptions
- Overview of ophthalmology biological brands in forecast
- Drug-specific forecast assumptions
- Lucentis
- Outlook for Lucentis
- First major-market biosimilar entrants
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Lucentis sales forecast for the United States: 2021-2031
- Lucentis sales forecast for the EU5: 2021-2031
- Lucentis sales forecast for Japan: 2021-2031
- Eylea
- Outlook for Eylea
- First major-market biosimilar entrants
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturing price assumptions
- Eylea sales forecast for the United States: 2021-2031
- Eylea sales forecast for the EU5: 2021-2031
- Eylea sales forecast for Japan: 2021-2031
- Lucentis
- Market forecast in the major pharmaceutical markets
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
